BioScience Health Innovations, Inc. financial statements
Income statement, balance sheet and cash flow statement for the last 7 fiscal years, taken from the XBRL data BioScience Health Innovations, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2020
FY2021
FY2022
FY2023
FY2023
FY2024
FY2025
Revenue
0
0
0
0.07
0.6
1.84
5.69
Cost of revenue
0.01
0.11
0.54
2.45
Gross profit
0.06
0.48
1.31
3.24
Research and development
0
0.03
0.16
Selling, general and administrative
0.01
0.03
0.09
0.15
0.71
1.15
2.21
General and administrative
0.01
Operating expenses
0.01
0.03
0.09
0.23
0.74
1.22
2.52
Operating income
-0.01
-0.03
-0.09
-0.17
-0.25
0.09
0.72
Interest expense
0
Other non-operating income
0
0.01
Pre-tax income
-0.03
-0.08
Income tax
0
0
0
0
0
0
0.08
Net income
-0.01
-0.03
-0.08
-0.17
-0.25
0.09
0.64
EPS, basic
0.00
0.00
-0.01
0.01
0.06
EPS, diluted
0.00
0.00
-0.01
0.01
0.06
Shares, basic (weighted)
3.79
5.46
33.8
10.5
11
Shares, diluted (weighted)
3.79
5.46
33.8
10.9
11.4
Balance sheet
FY2020
FY2021
FY2022
FY2023
FY2023
FY2024
FY2025
Cash and equivalents
0.02
0
0.02
0.01
0.02
0.66
0.66
Receivables
0.01
0.04
0.1
0.4
Inventory
0.01
0.04
0.06
0.34
Other current assets
0
0
0
0
0
0.02
Total current assets
0.02
0.01
0.02
0.03
0.09
0.85
1.56
Lease right-of-use assets
0
0.06
Intangible assets
0
0.03
0.08
Total assets
0.02
0.01
0.02
0.03
0.09
0.87
1.71
Accounts payable
0
0
0
0
0.01
0.01
0.01
Accrued liabilities
0
0
0
0.01
0.01
Deferred revenue
0
0
0.02
0.14
Total liabilities
0.01
0.02
0
0.05
0.1
0.04
0.23
Paid-in capital
0.02
0.02
0.13
0.16
0.42
1.17
1.18
Retained earnings
-0.01
-0.03
-0.12
-0.18
-0.43
-0.34
0.3
Shareholders' equity
0.01
-0.01
0.01
-0.02
-0.01
0.84
1.48
Total equity
0.01
-0.01
0.01
-0.02
-0.01
0.84
1.48
Total liabilities and equity
0.02
0.01
0.02
0.03
0.09
0.87
1.71
Shares outstanding
5.46
5.46
5.46
5.46
40.9
11
11
Cash flow statement
FY2020
FY2021
FY2022
FY2023
FY2023
FY2024
FY2025
Net income
-0.01
-0.03
-0.08
-0.17
-0.25
0.09
0.64
Stock-based compensation
0
0
Change in receivables
-0.01
-0.03
-0.06
-0.3
Change in inventory
-0.01
-0.03
-0.02
-0.28
Change in payables
0
0
0
-0.01
0
-0
Cash from operations
-0.01
-0.03
-0.09
-0.18
-0.31
0.02
0.17
Cash from investing
0
0
0
-0.03
-0.06
Debt repaid
0
-0
0
Stock issued
0.03
0
0.15
0.27
0.76
0
Cash from financing
0.03
0.01
0.1
0.19
0.32
0.65
-0.12
Net change in cash
0.02
-0.02
0.01
0.01
0.01
0.64
-0
Interest paid
0
0
0
0
0
0
0
Income taxes paid
0
0
0
0
0
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $7.11 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
53.8%
Gross profit / revenue.
Operating margin
-13.7%
Operating income / revenue.
Net margin
-14.7%
Net income / revenue.
Operating cash flow margin
-34.2%
Cash from operations / revenue.
Return on equity (ROE)
-35.9%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-30.8%
Net income / average total assets.
Return on invested capital (ROIC)
-43.2%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
2.5%
Research and development expense / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
208.3%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
334.5%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit growth, 1y
147.6%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
278.8%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating income growth, 1y
726.5%
Operating income vs the same period a year earlier. Only from a positive base.
Net income growth, 1y
638.0%
Net income vs the same period a year earlier. Only from a positive base.
EPS growth, 1y
500.0%
EPS vs the same period a year earlier. Only from a positive base.
Operating cash flow growth, 1y
642.5%
Operating cash flow vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
76.9%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
95.4%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
278.0%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Share count change, 1y
4.5%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$0.06
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.38
Revenue / diluted weighted shares.
Operating cash flow per share
-$0.13
Cash from operations / diluted weighted shares.
Book value per share
$0.16
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
18.6x
Market cap / revenue.
P/B
45.5x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
48.4x
Market cap / tangible book value, when positive.
EV/Sales
18.4x
Enterprise value / revenue.
Earnings yield
-0.8%
Net income / market cap (the inverse of P/E).
What was BioScience Health Innovations, Inc.'s revenue in fiscal 2025?
BioScience Health Innovations, Inc. reported revenue of $5.7M for fiscal 2025, 208.3% higher than the year before.
Was BioScience Health Innovations, Inc. profitable in fiscal 2025?
Yes. Net income was $642.1K, a net margin of 11.3%.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.